| Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, ... The lancet oncology 15 (4), 406-414, 2014 | 955 | 2014 |
| Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers S Loi, D Drubay, S Adams, G Pruneri, PA Francis, M Lacroix-Triki, ... Journal of clinical oncology 37 (7), 559-569, 2019 | 724 | 2019 |
| Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose … L Gianni, E Munzone, G Capri, F Fulfaro, E Tarenzi, F Villani, C Spreafico, ... Journal of clinical oncology 13 (11), 2688-2699, 1995 | 672 | 1995 |
| A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases G Aurilio, D Disalvatore, G Pruneri, V Bagnardi, G Viale, G Curigliano, ... European journal of cancer 50 (2), 277-289, 2014 | 339 | 2014 |
| Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer G Curigliano, G Viale, V Bagnardi, L Fumagalli, M Locatelli, N Rotmensz, ... Journal of clinical oncology 27 (34), 5693-5699, 2009 | 338 | 2009 |
| The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper M Cristofanilli, JY Pierga, J Reuben, A Rademaker, AA Davis, DJ Peeters, ... Critical reviews in oncology/hematology 134, 39-45, 2019 | 259 | 2019 |
| Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications F Nole, E Munzone, L Zorzino, I Minchella, M Salvatici, E Botteri, M Medici, ... Annals of Oncology 19 (5), 891-897, 2008 | 235 | 2008 |
| Paclitaxel in Metastatic Breast Cancer:-a Trial of Two Doses by a 3-Hour Infusion in Patients With Dith Disease Recurrence After Prior Therapy With Anthracyclines L Gianni, E Munzone, G Capri, F Villani, C Spreafico, E Tarenzi, F Fulfaro, ... JNCI: Journal of the National Cancer Institute 87 (15), 1169-1175, 1995 | 173 | 1995 |
| Clinical overview of metronomic chemotherapy in breast cancer E Munzone, M Colleoni Nature reviews Clinical oncology 12 (11), 631-644, 2015 | 163 | 2015 |
| Should liver metastases of breast cancer be biopsied to improve treatment choice? G Curigliano, V Bagnardi, G Viale, L Fumagalli, N Rotmensz, G Aurilio, ... Annals of oncology 22 (10), 2227-2233, 2011 | 156 | 2011 |
| Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized … OD Gentilini, E Botteri, C Sangalli, V Galimberti, M Porpiglia, R Agresti, ... JAMA oncology 9 (11), 1557-1564, 2023 | 143 | 2023 |
| Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women E Botteri, E Munzone, N Rotmensz, C Cipolla, V De Giorgi, B Santillo, ... Breast cancer research and treatment 140, 567-575, 2013 | 142 | 2013 |
| Pharmacokinetics of anticancer agents in patients with impaired liver function MG Donelli, M Zucchetti, E Munzone, M D’Incalci, A Crosignani European journal of cancer 34 (1), 33-46, 1998 | 140 | 1998 |
| Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial … G Pruneri, KP Gray, A Vingiani, G Viale, G Curigliano, C Criscitiello, ... Breast cancer research and treatment 158 (2), 323-331, 2016 | 126 | 2016 |
| Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer E Munzone, F Nolé, A Goldhirsch, E Botteri, A Esposito, L Zorzino, ... Clinical breast cancer 10 (5), 392-397, 2010 | 119 | 2010 |
| Breast cancer vaccines: a clinical reality or fairy tale? G Curigliano, G Spitaleri, E Pietri, M Rescigno, F De Braud, A Cardillo, ... Annals of Oncology 17 (5), 750-762, 2006 | 115 | 2006 |
| Optic nerve disturbances: a new form of paclitaxel neurotoxicity G Capri, E Munzone, E Tarenzi, F Fulfaro, L Gianni, A Caraceni, C Martini, ... Journal of the National Cancer Institute 86 (14), 1099-1101, 1994 | 113 | 1994 |
| Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy E Munzone, G Curigliano, A Rocca, G Bonizzi, G Renne, A Goldhirsch, ... Breast Cancer Research 8, 1-4, 2005 | 106 | 2005 |
| Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer E Botteri, MT Sandri, V Bagnardi, E Munzone, L Zorzino, N Rotmensz, ... Breast cancer research and treatment 122, 211-217, 2010 | 99 | 2010 |
| A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma A Rocca, S Minucci, G Tosti, D Croci, F Contegno, M Ballarini, F Nolè, ... British journal of cancer 100 (1), 28-36, 2009 | 95 | 2009 |
Marco ColleoniDirettore, Divisione di Senologia Medica, Istituto Europeo di Oncologia, Milano在 ieo.it 的电子邮件经过验证
